全文获取类型
收费全文 | 368812篇 |
免费 | 11158篇 |
国内免费 | 839篇 |
专业分类
耳鼻咽喉 | 3504篇 |
儿科学 | 12728篇 |
妇产科学 | 7780篇 |
基础医学 | 43833篇 |
口腔科学 | 7736篇 |
临床医学 | 27229篇 |
内科学 | 75298篇 |
皮肤病学 | 6015篇 |
神经病学 | 33524篇 |
特种医学 | 13091篇 |
外国民族医学 | 3篇 |
外科学 | 49451篇 |
综合类 | 3107篇 |
一般理论 | 74篇 |
预防医学 | 38668篇 |
眼科学 | 6544篇 |
药学 | 23572篇 |
中国医学 | 1325篇 |
肿瘤学 | 27327篇 |
出版年
2023年 | 1435篇 |
2022年 | 2110篇 |
2021年 | 5199篇 |
2020年 | 3048篇 |
2019年 | 4902篇 |
2018年 | 27616篇 |
2017年 | 21088篇 |
2016年 | 23527篇 |
2015年 | 6245篇 |
2014年 | 7405篇 |
2013年 | 10148篇 |
2012年 | 21564篇 |
2011年 | 35593篇 |
2010年 | 26356篇 |
2009年 | 17715篇 |
2008年 | 31222篇 |
2007年 | 33692篇 |
2006年 | 12469篇 |
2005年 | 13671篇 |
2004年 | 13840篇 |
2003年 | 13797篇 |
2002年 | 11234篇 |
2001年 | 3917篇 |
2000年 | 4100篇 |
1999年 | 3379篇 |
1998年 | 1450篇 |
1997年 | 1126篇 |
1996年 | 946篇 |
1995年 | 795篇 |
1994年 | 719篇 |
1993年 | 572篇 |
1992年 | 1573篇 |
1991年 | 1417篇 |
1990年 | 1390篇 |
1989年 | 1210篇 |
1988年 | 1095篇 |
1987年 | 1063篇 |
1986年 | 998篇 |
1985年 | 921篇 |
1984年 | 728篇 |
1983年 | 606篇 |
1979年 | 661篇 |
1978年 | 423篇 |
1974年 | 598篇 |
1973年 | 520篇 |
1972年 | 455篇 |
1971年 | 410篇 |
1970年 | 504篇 |
1969年 | 464篇 |
1968年 | 436篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
Del Lama Rafael Silva Candido Raquel Mariana Chiari-Correia Natália Santana Nogueira-Barbosa Marcello Henrique de Azevedo-Marques Paulo Mazzoncini Tinós Renato 《Journal of digital imaging》2022,35(3):446-458
Journal of Digital Imaging - Vertebral Compression Fracture (VCF) occurs when the vertebral body partially collapses under the action of compressive forces. Non-traumatic VCFs can be secondary to... 相似文献
73.
74.
75.
Tormo Nuria Giménez Estela Martínez-Navarro María Albert Eliseo Navalpotro David Torres Ignacio Gimeno Concepción Navarro David 《European journal of clinical microbiology & infectious diseases》2022,41(4):657-662
European Journal of Clinical Microbiology & Infectious Diseases - We compared the performance of an in-house-developed flow cytometry assay for intracellular cytokine staining (FC-ICS) and a... 相似文献
76.
Judith Brock Andreas Schmid Thomas Karrasch Petra Pfefferle Jutta Schlegel Inga Busse Annette Hauenschild Barbara Schmidt Maria Koukou Efthymia Arapogianni Andreas Schultz Miriam Thomalla Secil Akinci Johannes Kruse Winfried Padberg Andreas Schffler Jens Albrecht 《Clinical endocrinology》2019,91(3):400-410
77.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献78.
79.
80.
Flavia Temperilli Aldona Rina Isabella Massimi Anna Lisa Montemari Maria Luisa Guarino Alessandra Zicari 《Platelets》2015,26(8):783-787
Serum thromboxane-B2 (TxB2), together with arachidonic acid (AA)-induced platelet aggregation, are, at the moment, the most used tests to identify patients displaying high on-aspirin treatment platelet reactivity (HAPR). Both tests are specific for aspirin action on cyclooxygenase-1. While the correlation between serum TxB2 assay and clinical outcome is established, data are conflicting with regard to aspirin treatment and a possible association with AA-stimulated platelet markers and clinical outcome. To understand such discrepancy, we performed a retrospective study to compare both assays. We collected data from 132 patients receiving a daily dose of aspirin (100?mg/day) and data from 48 patients receiving aspirin on alternate days. All Patients who received a daily dose of aspirin were studied for AA-induced platelet aggregation together with serum TxB2 levels and AA-induced TxB2 formation was also studied in 71 patients out of entire population. Consistent with recommendations in the literature, we defined HAPR by setting a cut-off point at 3.1?ng/ml for serum levels of thromboxane B2 and 20% for AA-induced platelet aggregation. According to this cut-off point, we divided our overall population into two groups: (1) TxB2?<?3.1?ng/ml and (2) TxB2?>?3.1?ng/ml. We found low agreement between such tests to identify patients displaying HAPR. Our results show that AA-induced platelet aggregation >20% identify a smaller number of HAPR patients in comparison with TxB2. A good correlation between serum TxB2 and arachidonic acid-induced TxB2 production was found (r?=?0.76619). 相似文献